Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Back pain, Condition aggravated, Disturbance in attention, Headache, Hypoaesthesia
Clinical narrative: Dose Number 4; Severe headache; increased numbness; increase in neurological deficits related to MS (increased numbness; pain in back; R ribcage; eye pressure; difficulty sleeping; tenderness of skin; difficulty concentrating; increase in neurological deficits related to MS; increase in neurological deficits related to MS; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 49 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 03Feb2022 13:00 (Batch/Lot number: unknown) at the age of 49 years as dose 4, single for covid-19 immunisation. Relevant medical history included: "Multiple Sclerosis" (unspecified if ongoing); "Thyroid Cancer" (unspecified if ongoing); "Colon Cancer" (unspecified if ongoing); "penicillin allergy" (unspecified if ongoing), notes: Known allergies: penicillin. The patient took concomitant medications. The patient did not received any other vaccine in four weeks. Patient did not tested for Covid prior vaccination or post vaccination. Past drug history included: Clindamycin for drug allergy. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for Covid-19 Immunization; Bnt162b2 (DOSE 2, SINGLE), for Covid-19 Immunization; Bnt162b2 (DOSE 3 (BOOSTER), SINGLE), for COVID-19 immunization. The following information was reported: MULTIPLE SCLEROSIS (medically significant), NERVOUS SYSTEM DISORDER (non-serious) all with onset 03Feb2022, outcome "not recovered" and all described as "increase in neurological deficits related to MS"; INCORRECT DOSE ADMINISTERED (non-serious) with onset 03Feb2022 13:00, outcome "unknown", described as "Dose Number 4"; HEADACHE (non-serious) with onset 03Feb2022, outcome "not recovered", described as "Severe headache"; HYPOAESTHESIA (non-serious) with onset 03Feb2022, outcome "not recovered", described as "increased numbness"; CONDITION AGGRAVATED (non-serious) with onset 03Feb2022, outcome "not recovered", described as "increase in neurological deficits related to MS (increased numbness"; BACK PAIN (non-serious) with onset 03Feb2022, outcome "not recovered", described as "pain in back"; MUSCULOSKELETAL CHEST PAIN (non-serious) with onset 03Feb2022, outcome "not recovered", described as "R ribcage"; OCULAR DISCOMFORT (non-serious) with onset 03Feb2022, outcome "not recovered", described as "eye pressure"; INSOMNIA (non-serious) with onset 03Feb2022, outcome "not recovered", described as "difficulty sleeping"; PAIN OF SKIN (non-serious) with onset 03Feb2022, outcome "not recovered", described as "tenderness of skin"; DISTURBANCE IN ATTENTION (non-serious) with onset 03Feb2022, outcome "not recovered", described as "difficulty concentrating". Therapeutic measures were not taken as a result of multiple sclerosis, incorrect dose administered, headache, hypoaesthesia, condition aggravated, back pain, musculoskeletal chest pain, ocular discomfort, insomnia, pain of skin, disturbance in attention, nervous system disorder.  The lot number for bnt162b2 was not provided and will be requested during follow up.